PRLD — Prelude Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $234.27m
- $82.51m
- $12.14m
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview
Prelude Therapeutics Q1 net loss narrows as expenses fall
Brief: Prelude Therapeutics Q1 EPS USD -0.13
Prelude Therapeutics reports $99.5 mln net loss for 2025
Brief: Prelude Therapeutics FY EPS USD -1.29
U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug
Brief: Prelude Therapeutics Receives FDA Clearance Of Investigational New Drug Application (Ind) For Prt12396, A Mutant-Selective Jak2v617f Inhibitor
Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
Prelude Therapeutics Q3 net loss narrows
Brief: Prelude Therapeutics Q3 EPS USD -0.26
Brief: Prelude, Incyte Sign Exclusive Option Deal To Advance JAK2V617F JH2 Inhibitors For Cancer Therapy
Prelude Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Prelude Therapeutics Q2 EPS USD -0.41
Prelude Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview